Tarsus Pharmaceuticals to Participate in Major Investor Conferences in September

IRVINE, Calif., Sept. 01, 2026 /CourierPR/ -- Tarsus Pharmaceuticals, Inc., the biopharmaceutical company specializing in innovative treatments for unmet medical needs, including eye care, will participate in two major investor conferences in September.

On September 8th, Tarsus's management will attend the Wells Fargo 21st Annual Healthcare Conference. Following this, on September 15th, management will take part in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for 6:00 a.m. PT / 9:00 a.m. ET.

Investors will have the opportunity to engage with Tarsus executives at both events. Live webcasts will be available on the company’s website, and replays will be accessible within 48 hours, with limited archiving.

Tarsus Pharmaceuticals, founded to apply scientific and technological advancements to address unmet medical needs, particularly in the field of eye care, is advancing its pipeline to tackle several diseases. The company's XDEMVY® (lotilaner ophthalmic solution) 0.25% is FDA-approved for the treatment of Demodex blepharitis. Additionally, TP-04 is in Phase 2 development for the potential treatment of ocular rosacea, while TP-05, an oral tablet, is being developed for the potential prevention of Lyme disease. IRX-101, an ocular antiseptic, is also in the pipeline.

The company’s commitment to addressing unmet medical needs through advanced science and technology positions it as a key player in the pharmaceutical industry.